Review




Structured Review

Mimetics helix b surface peptide hbsp
Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and <t>HBSP/cibinetide)</t> mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.
Helix B Surface Peptide Hbsp, supplied by Mimetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/helix+b+surface+peptide+hbsp/alpha+helix+inducers+non+peptide/pmc12875903-70-19-3
Average 86 stars, based on 1 article reviews
helix b surface peptide hbsp - by Bioz Stars, 2026-10
86/100 stars

Images

1) Product Images from "Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy"

Article Title: Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy

Journal: Frontiers in Neurology

doi: 10.3389/fneur.2025.1665405

Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and HBSP/cibinetide) mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.
Figure Legend Snippet: Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and HBSP/cibinetide) mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.

Techniques Used:

Related Articles

Derivative Assay:

Article Title: Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy
Article Snippet: .. Peptide truncation and mimetics : Efforts to minimize molecule size while retaining function have led to the development of helix-B surface peptide (HBSP) and EPObis, short synthetic peptides derived from the EPO binding interface ( , ). ..

Binding Assay:

Article Title: Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy
Article Snippet: .. Peptide truncation and mimetics : Efforts to minimize molecule size while retaining function have led to the development of helix-B surface peptide (HBSP) and EPObis, short synthetic peptides derived from the EPO binding interface ( , ). ..



Similar Products

86
Mimetics helix b surface peptide hbsp
Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and <t>HBSP/cibinetide)</t> mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.
Helix B Surface Peptide Hbsp, supplied by Mimetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/helix+b+surface+peptide+hbsp/alpha+helix+inducers+non+peptide/pmc12875903-70-19-3
Average 86 stars, based on 1 article reviews
helix b surface peptide hbsp - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and HBSP/cibinetide) mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.

Journal: Frontiers in Neurology

Article Title: Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy

doi: 10.3389/fneur.2025.1665405

Figure Lengend Snippet: Schematic overview of erythropoietin (EPO) and engineered derivatives in traumatic brain injury (TBI). The diagram illustrates phase-specific mechanisms by which EPO and its engineered derivatives (carbamylated EPO, asialo-EPO, darbepoetin alfa, and HBSP/cibinetide) mitigate secondary brain injury. HBSP and CEPO are βcR-biased ligands that preferentially activate cytoprotective PI3K–AKT and NF-κB pathways, whereas darbepoetin alfa retains STAT5 signaling associated with erythropoiesis. Color coding: orange = JAK2/STAT5; blue = PI3K/AKT; teal = MAPK/ERK; purple = INPP5D/NF-κB.

Article Snippet: Peptide truncation and mimetics : Efforts to minimize molecule size while retaining function have led to the development of helix-B surface peptide (HBSP) and EPObis, short synthetic peptides derived from the EPO binding interface ( , ).

Techniques: